Biomarkers for the early detection of clear cell OC and targets for immunotherapy both have the potential to improve outcomes for patients. Our review aims to evaluate the existing literature to determine whether any antigens could fulfil this remit.

Methods A literature search was carried out to identify biomarkers using the following free text and MeSH terms: ('clear cell' OR 'clear-cell') AND (ovar*) AND (cancer* OR malignan* OR tumour* OR tumor* OR neoplasm* OR carcinoma*) AND (biomarker* OR protein* OR antigen* OR target*) AND (immuno* OR treat* OR diagnosis OR detect*). Inclusion criteria was primary research articles on human adult females including at least 10 clear cell carcinoma patients. Exclusion criteria included reviews; case series and reports paediatrics; animal; cell line; clear cell recurrence; metastasis from another primary cancer and prognostic biomarker studies.

Results 6,750 articles were identified from searching multiple databases from 1904–2021. Duplicates were removed (n=2076) and all texts were screened against the inclusion and exclusion criteria which identified 24 gene transcripts/proteins and 2 antibodies within 32 articles identifying single or multiple targets.

Conclusions Current findings suggest there are possible candidates to act as biomarkers and targets for immunotherapy. The biomarkers show a sensitivity and specificity up to 100% in single and multiple targets when differentiating clear cell from other subtypes of epithelial OC. With further analysis this will show the potential of these biomarkers to act as targets for immunotherapy.

EPV179/#184 EVALUATION OF THE SENSITIVITY TO DIFFERENT CHEMOTHERAPY REGIMENS IN PLATINUM—PARTIAL SENSITIVE RECURRENT OVARIAN CANCER

Y Wang, J Su, J Wang*. *Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Department of The Central Laboratory, Changsha, China*

10.1136/ijgc-2021-IGCS.250

Objectives Ovarian cancer is one of the highest incidence and mortality gynecological tumors. Most of them will relapse within 24 months. The purpose of this study was to compare the efficacy and safety of doxorubicin liposomes or paclitaxel combined with platinum chemotherapy in the treatment of some platinum-sensitive, recurrent ovarian cancer patients.

Methods Ovarian cancer patients who is recurrence in 6–12 months from the last chemotherapy were selected and randomly assigned in a 1:1 ratio to receive paclitaxel or doxorubicin liposome and platinum-based combinations. he primary endpoint is progression-free survival (PFS).

Results A total of 216 ovarian cancer patients were enrolled, 106 of whom received paclitaxel platinum therapy , 110 patients received doxorubicin platinum therapy. Patients in the platinum-based paclitaxel treatment group had a longer PFS (18.0 vs. 14.0 months, hazard ratio, 0.71, 95% confidence interval [CI], 0.44 to 1.45, P>0.05) compared with those in the doxorubicin-platinum group. The disease control rates of the two groups were 88.6% in the paclitaxel group and 86.36% in the doxorubicin group. In the study, the most adverse reactions of grade 3 or 4 in the doxorubicin platinum treatment group were leukopenia (6.4%) and thrombocytopenia (10.9%). The paclitaxel platinum treatment group were leukopenia (8.5%) and thrombocytopenia (3.8%).

Conclusions In the treatment of some platinum-sensitive, recurrent ovarian cancer patients, paclitaxel platinum-based therapy and doxorubicin-platinum therapy have no significant difference in efficacy, and there is no significant difference in adverse reactions. Therefore, in the treatment of platinum-sensitive, recurrent ovarian cancer patients, both options can be used as options. (ClinicalTrials.gov number, NCT04337632)

EPV180/#191 THE FEASIBILITY AND EFFICACY OF PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS UNDERGOING FRONTLINE TREATMENT OF OVARIAN CANCER

[1]J How*, [2]B Fellman, [1]S Westin, [1]A Sood, [1]N Fleming, [2]Y Yuan, [1]A Shafer, [1]B Zand, [1]K Schmeler, [3]A Nick, [1]K Lu, [4]RL Coleman, [1]A Jazaeri. *[1]The University of Texas MD anderson Cancer Center, Gynecologic Oncology and Reproductive Medicine, Houston, USA; [2]The University of Texas MD Anderson Cancer Center, Biostatistics, Houston, USA; [3]Tennessee Oncology, Gynecologic Oncology, Nashville, USA; [4]Department of Gynecologic Oncology, Us Oncology Research, The Woodlands, USA*

10.1136/ijgc-2021-IGCS.251

Objectives We report results of a phase II, open-label study evaluating the combination of pembrolizumab with carboplatin/paclitaxel in previously untreated advanced ovarian cancer patients (NCT02520154).

Methods Eligible patients were women with advanced high-grade epithelial non-mucinous ovarian cancer who had received up to 4 cycles of neoadjuvant carboplatin/paclitaxel chemotherapy and planned for interval cytoreduction. Following interval surgery, patients received adjuvant intravenous carboplatin/weekly paclitaxel/pembrolizumab for 3 cycles then maintenance pembrolizumab until progression, toxicity, or maximum of 20 cycles. The primary endpoint was progression-free survival (PFS). Secondary endpoints included feasibility, toxicity, and overall survival (OS).

Results Twenty-six patients were enrolled with a median follow-up of 26.9 months (range 11.0 – 49.5). Median age was 59 years and predominant histology was high grade serous (88.5%). At interval cytoreductive surgery, complete gross resection (CGR) was achieved in 21 (80.8%); 3 (11.5%) had optimal non-CGR, and 2 (7.7%) had suboptimal cytoreduction. Median PFS was 14.2 months (95% CI 12.4 – 23.0). All patients completed 3 planned cycles of carboplatin/paclitaxel/pembrolizumab. Median number of maintenance cycles was 6 with all 20 cycles completed in 6 patients. Grade 3/4 treatment-related adverse events occurred in 19 (73.1%) patients. Treatment discontinuation due to disease progression occurred in 9 patients (34.6%) and due to immune-related toxicity in 6 patients (28.6%), most commonly attributable to hepatotoxicity (n=3).

Conclusions Combining pembrolizumab with carboplatin/paclitaxel for advanced ovarian cancer patients in the frontline setting was feasible, tolerable, and resulted in PFS within the historical range for this patient population. OS is immature and translational endpoints are pending.